Erin Horn is a healthcare industry executive with a successful track record in market access leadership and product launch experience with Iveric Bio, Aerie, Alcon, and Novartis.
She has 25 years of pharmaceutical experience across, sales, training, leadership, and market access functions in both traditional and specialty buy-and-bill ophthalmic pharmaceuticals. Prior to Sydnexis Inc., Erin led the pre- and post-launch market access function with Iveric Bio, helping patients and their caregivers gain broad access to a novel treatment in the retina space for geographic atrophy.
Prior to Iveric Bio, Erin was Senior Director, Market Access at Aerie Pharmaceuticals where she successfully launched both Rocklatan and Rhopressa for glaucoma. Erin also led Market Access teams at Alcon, launching multiple key ophthalmic and otic pharmaceuticals.
Before Erin was a market access executive, she was a sales leader across numerous therapeutic areas at Alcon."
